BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119684 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Claudia Sorbi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy. Hauptthemen laut MEDLINE: Melanoma, Receptors, sigma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Modena and Reggio Emilia.
Abstract (Originalsprache)
The management of advanced-stage melanoma is clinically challenging, mainly because of its resistance to the currently available therapies. Therefore, it is important to develop alternative therapeutic strategies. The sigma-2 receptor (S2R) is overexpressed in proliferating tumor cells and represents a promising vulnerability to target. Indeed, we have recently identified a potent S2R modulator (BS148) that is effective in melanoma. To elucidate its mechanism of action, we designed and synthesized a BS148 fluorescent probe that enters SK-MEL-2 melanoma cells as assessed using confocal microscopy analysis. We show that S2R knockdown significantly reduces the anti-proliferative effect induced by BS148 administration, indicating the engagement of S2R in BS148-mediated cytotoxicity. Interestingly, BS148 treatment showed similar molecular effects to S2R RNA interference-mediated knockdown. We demonstrate that BS148 administration activates the endoplasmic reticulum stress response through the upregulation of protein kinase R-like ER kinase (PERK), activating transcription factor 4 (ATF4) genes, and C/EBP homologous protein (CHOP). Furthermore, we show that BS148 treatment downregulates genes related to the cholesterol pathway and activates the MAPK signaling pathway. Finally, we translate our results into patient-derived xenograft (PDX) cells, proving that BS148 treatment reduces melanoma cell viability and migration. These results demonstrate that BS148 is able to inhibit metastatic melanoma cell proliferation and migration through its interaction with the S2R and confirm its role as a promising target to treat cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
- Hematology Section, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy.
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy.
- Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
- Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Ospedale di Baggiovara, 41126 Modena, Italy.
- Center for Genomic Research, University of Modena and Reggio Emilia, 41125 Modena, Italy.
ORCID-Profile: Silvia Belluti, Claudio Giacinto Atene, Pasquale Linciano, Neena Roy, Livio Casarini, Tommaso Zanocco-Marani, Luisa Lanfrancone, Carol Imbriano, Silvia Franchini
Förderung
- University of Modena and Reggio Emilia
Zitieren
APA
Sorbi, C., Belluti, S., Atene, C. G., Marocchi, F., Linciano, P., Roy, N., Paradiso, E., Casarini, L., Ronsisvalle, S., Zanocco-Marani, T., Brasili, L., Lanfrancone, L., Imbriano, C., Di Rocco, G., & Franchini, S. (2023). BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119684
Vancouver
Sorbi C, Belluti S, Atene CG, Marocchi F, Linciano P, Roy N, et al. BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119684
BibTeX
@article{Sorbi2023,
author = {Sorbi, Claudia and Belluti, Silvia and Atene, Claudio Giacinto and Marocchi, Federica and Linciano, Pasquale and Roy, Neena and Paradiso, Elia and Casarini, Livio and Ronsisvalle, Simone and Zanocco-Marani, Tommaso and Brasili, Livio and Lanfrancone, Luisa and Imbriano, Carol and Di Rocco, Giulia and Franchini, Silvia},
title = {BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119684}
}
EUVIMED